Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: trouble (31), riot (2), disorder (273)

Carboplatin(AUC2)-Paclitaxel RT

Description: Chemotherapy Protocol GASTROINTESTINAL (UPPER) CANCER CARBOPLATIN (AUC2)-PACLITAXEL-RADIOTHERAPY Regimen • Gastrointestinal (Upper) Cancer – Carboplatin(AUC2)-Paclitaxel-Radiotherapy Indication • Neoadjuvant treatment of
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Upper-gastro-intestinal/CarboplatinAUC2-Paclitaxel-RT.pdf

Neuroendocrine-Sunitinib Ver 1

Description: Chemotherapy Protocol NEUROENDOCRINE SUNITINIB Regimen Neuroendocrine - Sunitinib Indication The 1st, 2nd or 3rd line treatment of pancreatic neuroendocrine carcinomas that are
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Endocrinecancer/Neuroendocrine-Sunitinib-Ver-1.pdf

Distinguishing mental disorder from mental incapacity: a brief guide

Description: Distinguishing mental disorder from mental incapacity poses a problem for clinicians.
Url: /HealthProfessionals/Clinical-law-updates/Distinguishing-mental-disorder-from-mental-incapacity.aspx

People who refuse medical or surgical treatment for self inflicted injury

Description: Auto Generated Title On these pages I discuss the clinical law on which our nursing and medical staff rely when caring for
Url: /HealthProfessionals/Clinical-law-updates/People-who-refuse-medical-or-surgical-treatment-for-self-inflicted-injury.aspx

Erdafitinib

Description: Regimen • Urothelial - Erdafitinib Chemotherapy Protocol UROTHELIAL CANCER ERDAFITINIB Indication • Monotherapy treatment of unresectable or metastatic urothelial cancer harbouring a susceptible fibroblast
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Erdafitinib.pdf

Papers Trust Board - 5 November 2024

Description: Date Time Location Chair Apologies Agenda Trust Board – Open Session 05/11/2024 9:00 - 11:30 The Ark Conference Centre
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2024-Trust-documents/Papers-Trust-Board-5-November-2024.pdf

Atezolizumab (1875mg 21-days) SC

Description: Chemotherapy Protocol UROTHELIAL CANCER Atezolizumab SC (1875mg – 21 days) Regimen • Urothelial cancer – Atezolizumab monotherapy (1st or 2nd line) Indications • First line
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Atezolizumab-SC-1875mg-21-days.pdf

Papers Trust Board - 10 September 2024

Description: Agenda Trust Board – Open Session Date 10/09/2024 Time 9:00 - 13:00 Location Conference Room, Heartbeat/Microsoft Teams Chair
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2024-Trust-documents/Papers-Trust-Board-10-September-2024.pdf

Capecitabine-TrastuzumabIV-Tucatinib

Description: Chemotherapy Protocol BREAST CANCER Capecitabine–Trastuzumab (IV)-Tucatinib Regimen • Breast Cancer – Capecitabine–Trastuzumab (IV)-Tucatinib Indication t • Treatment of over-expressed
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Capecitabine-Trastuzumab-IV-Tucatinib.pdf

Papers Trust Board - 25 July 2024

Description: Agenda Trust Board – Open Session Date 25/07/2024 Time 9:00 - 13:00 Location Anaesthetic Seminar Room (CE95/99), E
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2024-Trust-documents/Papers-Trust-Board-25-July-2024.pdf

201 to 210 of 282

Previous … 19 20 21 22 23 … Next